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Treatment with IMiDs and/or PI pre-transplant was associ-
ated with better survival versus no prior exposure to these
agents but this was not statistically significant (P = .11)
(Figure 2).
In this analysis, we show that a significant number of pa-
tients undergo delayed ASCT for MM. Outcomes of ASCT after
L1 and L2 were similar. This being a retrospective study, we
cannot asses the number of patients who intended to but were
not able to undergo delayed ASCT. Exposure to one or both
highly active anti-myeloma agents (IMids and PI) before ASCT
was associated with better post transplant outcomes.
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Introduction: Approximately 10-30% of candidates to au-
tologous hematopoietic stem cell transplant (HSCT) are unable
to collect an adequate yield of CD34+ cells/kg. Peripheral blood
stem cell (PBSC) mobilization strategies vary considerably but
the optimal methodology for mobilizing PBSC is not well
defined. Plerixafor (Mozobil®) is approved for the mobili-
zation of PBPC in combination with G-CSF at a dose of
.24 mg/kg once daily for up to 4 consecutive days; however,
it is an expensive drug and is expected to increase costs as-
sociated with PBSC harvest. We aim to investigate the safety
and efficacy of the administration of low-dose plerixafor in
mobilizing CD34+ cells plus G-CSF in MM and lymphoma.
Methods: It is a preliminary report of a single-institution,
open-label, phase II trial to test the feasibility and efficacy
for mobilization of low-dose plerixafor added to daily G-CSF
in patients with MM or NHL undergoing autologous HSCT.
The mobilization protocol consisted of G-CSF (10 μg/kg) sub-
cutaneously daily for 4 days and plerixafor (.12 mg/kg)
administered subcutaneously 11 hr prior to apheresis. Stem
cells collection was performed with a Cobe Spectra® or
Spectra Optia® apheresis system. The planned target blood
volume to be processed was 4-fold total blood volume. Pe-
ripheral blood CD34+ counts were analyzed using flow
cytometry. Primary endpoint was the proportion of pa-
tients achieving at least 2 × 106 CD34+cells/kg in 1 apheresis
harvest. Secondary end points included the rate of success-
ful CD34+ cell mobilization, defined as a peak of CD34+ cells
in PB >20 cells/mL. Wemeasure PB CD34+ cells the day 4 and
5 after plerixafor administration. Toxicities and engraft-
ment were documented.
Results: Fifteen patients have been enrolled. Eight with MM,
5 with NHL, and 2 HL. The median PB CD34+ cell count for
patients on day 4 before receiving plerixafor was 12.3/mL
(range, 2.2-168.8) whereas on day 5 after plerixafor was
50.8/mL (range, 8.2-360.7) (P = .001). The median collection
yield was 4.5 × 106 CD34+ cells/Kg (range, 1.27 – 24.5 million
CD34+ cells/Kg). Plerixafor was well tolerated in most pa-
tients, only 2 referred moderate diarrhea. Thirteen of the 15
patients reached the target cell count (86%) with only 1 day
of collection. Median neutrophil and platelet engraftment of
12 (range, 9-18) and 12 days (range, 9-16), respectively. Two
patients are on day +2 and +6 and waiting for engraftment.
Conclusions: Failure of PBSC mobilization is a critical issue
for MM and NHL patients undergoing autologous HSCT. The
combination of low-dose plerixafor with G- CSF in this study
achieved 86% of successful yields, and appears to be an ef-
ficient and safe approach in first-line to improve the success
of the yield. Aside of the costs related to plerixafor, this strat-
egy can be counterweighed by reducing other resources as
reducing number of apheresis and possibly reducing the
impact on quality of life for patients.
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Multiple myeloma (MM) is a neoplasm resulting from plasma
cells clonal proliferation. New therapies and Autologous He-
matopoietic Stem Cell Transplantation (HSCTa) routine use
have led to substantial improvements in overall response rate
and durable remissions.1 Its incidence increases with age and
about 63% of patients are over 65 years old at diagnosis,2
which, in most cases, impacts eligibility and performance at
the HSCTa.3 Patients younger than 65 years old, with no sig-
nificant co-morbidities and a good performance status, are
generally eligible for HSCTa as first-line treatment.1,4
This study aims to study retrospectively 96 patients between
25 and 74 years old, who had MM and performed their first
HSCTa from 2005 to 2016, in a large private hospital in São
Paulo. The following information regarding the transplant
moment was analyzed descriptively and quantitatively: de-
mographic data, MM subtype, Karnofsky Performance Status
(KPS), International Staging System (ISS) and Durie-Salmon
(DS) staging, pre-HSCTa disease status, incidence of relapse
and death for the study of outcomes, using Kaplan-Meier anal-
ysis and Log-Rank tests. The majority were male (61, 45%),
IgG secretors (60, 41%), DS III stage (44, 79%), ISS I (36, 45%),
KPS 90-100 (67, 7%), on partial clinical response to previous
treatment (65, 62%). Patients were divided into two groups
for comparison: 74 patients under 65 (Group 1) and 22 pa-
tients over 65 years old (Group 2). Group 1 had an average
overall survival (OS) of 9, 0 ± 0, 6 years (95% CI = 7, 7-10, 2)
and their OS probability was 89, 4% in one year, 70, 8% in five
and 67, 4% in ten years. Group 2 presented an average OS of
6, 7 ± 0, 9 years (95% CI = 5, 0-8, 5) and their probability of
OS was 94, 7% in one year, 73, 2% in five and 29, 3% in ten
years. There was no significant statistical difference in OS
between both groups. Group 1 disease-free survival (DFS)
probability was 80, 2% in one year, reaching 45, 7% and 15,
6% in five and 10 years, respectively. Group 2 DFS probabil-
ity was 90, 2% in one year, 38, 6% in five and 14.5% in ten years,
respectively. There was statistical difference in DFS between
the two groups only in patients submitted to HSCTa on ISS
III and patients with IgA subtype.
Thus, it can be inferred that age as an isolated factor should
not be used as an eligibility standard for HSCTa in patients
over 65 years old with MM.
This should be based on detailed multiprofessional assess-
ments allied to clinical evaluation of the patients’ condition,
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since HSCTamay be considered a first-line treatment for these
patients.
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Background: We retrospectively compared myeloma pa-
tients <65 years with >65 years of age, analyzing CD34
mobilization into peripheral blood and the number of
leukapheresis needed to collect at least one single stem cell
graft.
Material&Methods: From February 1999 through August
2017, data from 561 myeloma patients below the age of 65
were compared to 70myeloma patients above 65 years of age
who were eligible for auto HSCT according to geriatric
assessment (GA). All these data were obtained from the
Ankara University Faculty of Medicine Center for Therapeu-
tic Apheresis and written informed consent was signed
according to our institution regulations. Patients under-
went further PBSC collections until we obtained the target
dose >20 CD34+ cells/μL blood. A maximum of 3 collections
were performed in the first mobilization; if the cell dose was
not achieved, we submitted patients to a secondmobilization.
Results: Seventy of 631 patients were above 65 years of
age (median age 67, range 65-77) and 561 patients were
below the age of 65 (median age 54, range 29-64).
Baselinecharacteristics of the older and younger patient
cohorts are summarized in Table 1. The chemotherapy regi-
mens were not statistically different between both age groups
(chi square p value .28). The number of CD34-positive cir-
culating cells before scheduled leukapheresis was mean
66.58 ± 2.67 cells/μL (median 46 cells/ μL, range 2-397) in all
patients (including patients who failed mobilization).
Conclusion: Patients above 65 years of age have enough pro-
genitor cells in the actual graft but still the number is inferior
compared to the younger population and this can be over-
come by an increased number of leukaphereses.
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Objective: To evaluate the efficacy and tolerability of salvage
auto-HCT in the era of novel agents.
Patients and Methods: We conducted a retrospective anal-
ysis of 27 previously transplanted patients who underwent
repeat auto-HCT for relapsed MM at our institution between
June 2000 and May 2017. Patients underwent salvage auto-
HCT after prior single auto-HCT (n = 18), after prior tandem
auto-HCT (n = 7) or after 2 previous auto-HCT (n = 2). Pa-
tients who had two prior transplants (Two Prior Tx) were
grouped together (n = 9). Median age at salvage auto-HCT was
59 years (range: 48-72) and median interval to salvage auto-
HCT from last transplant was 58 months (range: 16-165).
Results: At a median follow up of 27 months, PFS and OS
between the two groups (One Prior Tx or Two Prior Tx) was
not statistically significantly different (PFS, P = .55; OS, P = .64).
Treatment related mortality (TRM) occurred in one patient in
the Two Prior Tx group at day +17 from refractory bacterial
infection. No TRMwas observed in the One Prior Tx group. One
patient in the Two Prior Tx group was diagnosed with treat-
ment related MDS at 9 months after salvage transplant and
died at 16 months of MDS related complications. Response to
salvage auto-HCT in the One Prior Tx and Two Prior Tx groups
was PR 28% and 14%, VGPR 50% and 71% and CR 17% and 14%,
respectively. One patient in the One Prior Tx had SD.
Conclusion: Therapeutic options for patients with relapsed
multiple myeloma (MM) following a prior auto-HCT might
include novel agents as well as salvage auto-HCT. This
retrospective analysis demonstrates that salvage auto-HCT is
tolerable and appears equally effective in patients having pre-
viously received one or two auto-HCT. The comparative
efficacy of novel agents versus salvage auto-HCT is unknown.
Our data suggest that salvage auto-HCT in selected patients
remains a viable option even in the era of novel agents.
Table 1
Patients Characteristics
Patients ≥65 years <65 years P < .05
Gender (M/F) (n) 53/17 344/217 .018
Median age (years (range)) 67 (65-77) 54 (29-64) .00*
Mobilization Regimens (n) .436
GCSF 58 (82.9%) 424 (75.6%)
Chemotherapy 11 (15.7%) 98 (22.1%)
Plerixafor 1 (1.4%) 13 (2.3%)
Median number of
leukapheresis (range)
2 (1-3) 2 (1-3) .48
Peripheral CD34 (+) cells/μL
(first mobilization attempt)
50.96 ± 7.04 68.57 ± 8.35 .006*
Mean CD34 (+) cells/ml
(×106/kg) (first mobilization
attempt)
4.53 ± 3.87 6.66 ± 1.34 .002*
S140 Abstracts / Biol Blood Marrow Transplant 24 (2018) S119–S290
